On y voit un peu plus NET entre streptozotocine-5FU et évérolimusRamon Salazar - Service d'oncologie médicale, Catalan Institute of Oncology (ICO), 08916 - L’Hospitalet de Llobregat, Barcelona/ES - Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206)
Cancers du pancréas métastatique : l’association gemcitabine – paclitaxel déçoit en 2e ligne…Christelle de la Fouchardiere (Centre Léon Bérard, 69008 - Lyon/FR) - LBA60 - Evaluation of gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma: Results of the randomized phase III PRODIGE 65 - UCGI 36 - GEMPAX UNICANCER study
Cancers oesogastriques ; même avec l’immuno on n’est pas prêt d’abandonner la chimio…Sylvie Lorenzen (Klinikum Rechts der Isar, Technische Universitat, 81675 - Munich) - Abstract 1203O - FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase II Moonlight trial of the AIO
L’immunothérapie dans le CCR métastatique MSIh/dMMR : toujours ! Et dès que possibleJulien Taieb, Gastroenterology And Digestive Oncology Department, Hopital European George Pompidou, 75015 - Paris/FR - Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): The SAMCO-PRODIGE 54 randomised phase II trial